References
1. Beresneva O.N., Parastaeva M.M., Ivanova G.T., et al. Changes in the cardiovascular system in rats associated with high consumption of sodium chloride. Arterial’naya gipertenziya [Arterial Hypertension]. 2014; 20 (5): 384–90. (in Russian)
2. Grigorova Y.N., Wei W., Petrashevskaya N., et al. Dietary sodium restriction reduces arterial stiffness, vascular TGF-β-dependent fibrosis and marinobufagenin in young normotensive rats. Int J Mol Sci. 2018; 19 (10): 232–41.
3. Grigorova Y.N., Juhasz O., Zernetkina V., et al. Aortic fibrosis, induced by high salt intake in the absence of hypertensive response, is reduced by a monoclonal antibody to marinobufagenin. Am J Hypertens. 2016; 29 (5): 641–6.
4. Yang G.H, Zhou X., Ji W.J., et al. VEGF-C-mediated cardiac lymphangiogenesis in high salt intake accelerated progression of left ventricular remodeling in spontaneously hypertensive rats. Clin Exp Hypertens. 2017; 39 (8): 740–7.
5. Kayukov I.G., Beresneva O.N., Parastaeva M.M., et al. Soy proteins anti-heart removal in Wistar rats receiving a diet with a high sodium chloride. Nefrologiya [Nephrology]. 2019; 23 (6): 92–9. (in Russian)
6. Parastaeva M.M., Beresneva O.N., Ivanova G.T., et al. Arterial hypertension and salt consumption: contribution to heart removal. Nefrologiya [Nephrology]. 2016; 20 (5): 97–105. (in Russian)
7. Oppelaar J.J., Vogt L. Body fluid-independent effects of dietary salt consumption in chronic kidney disease. Nutrients. 2019; 11: 2779.
8. Hosohata K. Biomarkers for chronic kidney disease associated with high salt intake. Int J Mol Sci. 2017; 18: 2080.
9. Smirnov A.V., Karunnaja A.V., Zarajskij M.I., et al. Expression of microRNA-21 in the urinbe in patients with nephropathies. Nefrologiya [Nephrology]. 2014; 18 (6): 59–63. (in Russian)
10. Kayukov I.G., Ivanova G.T., Zaraysky M.I., et al. Expression of microRNA-21 in the renal tissue and urine in rats with unilateral ureter obstruction. Nefrologiya [Nephrology]. 2016. 20 (5): 84–9. (in Russian)
11. Wang G. Kwan B.C., Lai F.M., Chow K.M., Li P.K., Szeto C.C. Elevated levels of miR-146a and miR-155 in kidney biopsy and urine from patients with IgA nephropathy. Dis Markers. 2011; 30: 171–9.
12. Yanai K., Kaneko S., Ishii H. et al. Quantitative real-time PCR evaluation of microRNA expressions in mouse kidney with unilateral ureteral obstruction. J Vis Exp. 2020; 27 (162): 185–2.
13. Beresneva O.N., Parastaeva M.M., Kucher A.G., et al. Effect of protein content in diet on progression of experimental chronic renal failure. Nefrologiya [Nephrology]. 2003; 7 (4): 66–70. (in Russian)
14. Smirnov A.V., Kucher A.G., Dobronravov V.A., et al. Dietary soy protein inhibits the development of interstitial renal fibrosis in rats with unilateral uretal obstruction: introduction to nutritive epigenomics. Nefrologiya [Nephrology]. 2012; 16 (4): 75–83. (in Russian)
15. Smirnov A.V., Beresneva O.N., Parastaeva M.M., et al. Effectiveness of the influence of low protein diets with the application of ketosteril and soy isolate on experimental renal failure. Nefrologiya i dializ [ Nephrology and Dialysis]. 2006; 8 (4): 344–50. (in Russian)
16. Ogborn M.R., Nitschmann E., Bankovic-Calic N., et al. Dietary soy protein benefit in experimental kidney disease is preserved after isoflavone depletion of diet. Exp Biol Med (Maywood). 2010; 235: 1315–20.
17. Liu Z.M., Ho S.C., Chen Y.M., et al. Effect of whole soy and purified isoflavone daidzein on renal function – a 6-month randomized controlled trial in equol-producing postmenopausal women with prehypertension. Clin Biochem. 2014; 47: 1250–6.
18. Ahmed M.S., Calabria A.C., Kirsztajn G.M. Short-term effects of soy protein diet in patients with proteinuric glomerulopathies. J Bras Nefrol. 2011; 33: 150–9.
19. Fouad M., Salem I., Elhefnawy K. et al. MicroRNA-21 as an early marker of nephropathy in patients with type 1 diabetes. Indian J Nephrol. 2020; 30 (1): 21–2.
20. Wang J.Y., Gao Y.B., Zhang N., et al. MicroRNA-21 overexpression enhances TGF-β1-induced epithelial-to-mesenchymal transition by target smad7 and aggravates renal damage in diabetic nephropathy. Mol Cell Endocrinol. 2014; 392 (1–2): 163–72.
21. Abdelghaffar S., Shora H., Abdelatty S., et al. MicroRNAs and risk factors for diabetic nephropathy in egyptian children and adolescents with type 1 diabetes. Diabetes Metab Syndr Obes. 2020; 13: 2485–4.
22. Kölling M., Kaucsar T., Schauerteetal C., et al. Therapeutic miR21 silencing ameliorates diabetic kidney disease in mice. Mol Ther. 2017; 25 (1): 165–80.
23. Parker E., McElroy P., Picut C., et al. Soy-deficient diet induces renal lesions in juvenile rats. Food Chem Toxicol. 2018; 121: 467–71.
24. Zhang H., Li W., Gu W., et al. MALAT1 accelerates the development and progression of renal cell carcinoma by decreasing the expression of miR-203 and promoting the expression of BIRC5. Cell Prolif. 2019; 52 (5): e12640.
25. Deng B., Wang B., Fang J., et al. MiRNA-203 suppresses cell proliferation, migration and invasion in colorectal cancer via targeting of EIF5A2. Sci Rep. 2016; 6: 28301.
26. Ge X.J., Zheng L.M., Feng Z.X., et al. H19 contributes to poor clinical features in NSCLC patients and leads to enhanced invasion in A549 cells through regulating miRNA-203-mediated epithelial-mesenchymal transition. Oncol Lett. 2018; 16 (4): 4480–8.
27. Kim J.S., Choi D.W., Kim C.S., et al. MicroRNA-203 induces apoptosis by targeting Bmi-1 in YD-38 oral cancer cells. Anticancer Res. 2018; 38 (6): 3477–85.
28. Wang J.-X., Zhang X.-J., Li Q., et al. MicroRNA-103/107 regulate programmed necrosis and myocardial ischemia/reperfusion injury through targeting FADD. Circ Res. 2015; 117 (4): 352–3.
29. Xu C., Lu Y., Pan Z., et al. The muscle-specific microRNAs miR-1 and miR-133 produce opposing effects on apoptosis by targeting HSP60, HSP70 and caspase-9 in cardiomyocytes. J Cell Sci. 2007; 120 (17): 3045–52.
30. Zong L., Wang W. CircANXA2 promotes myocardial apoptosis in myocardial ischemia-reperfusion injury via inhibiting miRNA-133 expression. Biomed Res Int. 2020; 2020: 8590861.
31. Sun B., Liu S., Hao R. et al. RGD-PEG-PLA delivers MiR-133 to infarct lesions of acute myocardial infarction model rats for cardiac protection. Pharmaceutics. 2020; 12 (6): 575.
32. Zhang X.G., Wang L.Q., Guan H.L. Investigating the expression of miRNA-133 in animal models of myocardial infarction and its effect on cardiac function. Eur Rev Med Pharmacol Sci. 2019; 23 (13): 5934–40.
33. Hirata H., Ueno K., Nakajima K., et al. Genistein downregulates onco-miR-1260b and inhibits Wnt-signaling in renal cancer cells. Br J Cancer. 2013; 108: 2070–8.
34. Ma J., Cheng L., Liu H., et al. Genistein down-regulates miR-223 expression in pancreatic cancer cells. Curr Drug Targets. 2013; 14 (10): 1150–6.
35. Biersack B. Current state of terpenoidal dietary factors and natural products as non-coding RNA/microRNA modularors for improved cancer therapy and prevention. Noncoding RNA Res. 2016; 1 (1): 12–34.